Swedish AI Precision Pathology 2 (SwAIPP2)
| Reference number | |
| Coordinator | Karolinska Institutet - Karolinska Institutet Inst f medicinsk epidemiologi & |
| Funding from Vinnova | SEK 15 887 767 |
| Project duration | September 2024 - September 2027 |
| Status | Ongoing |
| Venture | Utlysning Framtidens Precisionsmedicin |
| Call | The precision medicine of the future |
Purpose and goal
SwAIPP is a cross-sector innovation environment with research at the global forefront and demonstrated capability of innovation, clinical translation and implementation of AI-based precision pathology to improve cancer care. During the second phase of SwAIPP we are now adding new partners and diagnostic applications. We continue to work on compliance issues at the core of medical device development (CE-IVDR and cybersecurity), while streamlining clinical translation and market introduction.
Expected effects and result
1) Develop a world-class precision health environment for innovation and collaboration across academia, healthcare, and industry. 2) Streamline clinical translation and implementation of cutting-edge AI-based precision pathology in Sweden. 3) Develop, validate, and implement 1-2 additional regulatory-approved AI diagnostic solutions at scale. 4) Improve equality in access to precision diagnostics, ensuring sustainable delivery to patients.
Planned approach and implementation
SwAIPP-2 will be implemented through activities in the following work-packages: WP1. Project management. WP2. Translation and validation of new prototype AI-based diagnostic solutions WP3. Development and validation (evidence) of AI precision diagnostics for clinical use WP4. Regulatory routes and cybersecurity WP5. Internationalisation WP6. Infrastructure for clinical trials WP7. Deployment and real-world testing at additional Swedish healthcare providers WP8. Communication and dissemination